2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
13
NET
2
Endocrine
2
Tumor-Agnostic
1
Sarcoma
1
Gynecologic
1
Conditions
Neuroendocrine Tumors
2
Interventions
lutetium Lu 177 dotatate
48
Everolimus
40
Magnetic Resonance Spectroscopy
21
lanreotide
17
Temozolomide
17
gallium Ga 68 dotatate
15
Octreotide
15
pembrolizumab
13
Nivolumab
13
surufatinib
12
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
Sunitinib
10
pasireotide
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
Lutetium-177
9
3-Iodobenzylguanidine
9
Ga(III)-DOTATOC
8
Carboplatin
8
telotristat ethyl
6
copper dotatate CU-64
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Ipilimumab
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Yttrium-90
×
NET
×
Clear all
NCT04339036
2025-12-10
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled